As part of our specialized support for pharmaceutical cannabis investments, we supported the investment of Curity Pharma for the creation of the first hybrid greenhouse pharmaceutical cannabis facility in Europe — a project totaling approximately €20 million.
The investment was funded through a subsidy from the Development Law and simultaneously included in the loan component of the Recovery and Resilience Facility (RRF).
Company profile
Curity Pharma is a pharmaceutical company specializing in medical cannabis, aiming to become a top producer and distributor of premium-quality medical cannabis products across Europe. The company is committed to promoting research and development of the cannabis plant in Europe, in order to offer innovative medical products to the public.
The first hybrid greenhouse cannabis production facility in Europe is located in Larissa. At this site, Curity Pharma will produce pharmaceutical cannabis products expected to benefit a wide range of patients.
In parallel with its activities in Greece, the company is developing strategic partnerships and joint ventures in all European countries where medical cannabis is legal, for local distribution purposes.
How the funding supported the company’s goals
The funding enabled the realization of an investment on a total area of 67,000 m², with the production unit occupying 1,800 m².
This facility is divided into two main production lines — for inhalation and ingestion products — both fully equipped with cutting-edge machinery for the manufacturing and packaging of plant-based pharmaceutical products.
Curity Pharma aims to produce eight distinct products, enabling physicians to prescribe the most suitable formulation tailored to both immediate and long-term patient needs.
In its initial growth phase, the company plans to hire 60 highly trained employees across both agricultural and pharmaceutical production sectors, with potential for further recruitment in other areas in the future.
Future plans also include the development of new pharmaceutical forms of cannabis, providing doctors with additional valuable treatment tools.
Our role
VK PREMIUM, as a development consultant, contributed to the funding process by preparing and securing the approval of a low-interest subsidized loan from the Recovery and Resilience Facility (RRF), while also drafting and submitting the subsidy application under the Development Law.
Services provided:
- Preparation of the required techno-economic study for the investment plan, aiming at successful application approval.
- Close collaboration with the company to create a comprehensive business plan that maximized approval chances.
- Submission of a complete application file to the relevant authorities to ensure timely evaluation and approval.
- Coordination of all involved stakeholders.
Funded investment items
The company received approval for the funding of:
- Building infrastructure.
- Outdoor area development works.
- Machinery and related equipment.
- Intangible assets (e.g., software).
Benefits of combined funding from the Development Law and the RRF
The combination of a subsidy from the Development Law and a low-interest (subsidized) loan from the RRF provided the company with maximum financial benefit. It enabled Curity Pharma to enhance both the quality and scale of its offerings and significantly boosted its reputation and brand recognition.
We can make a decisive contribution to the growth of Greek businesses.
With 18 years of experience and nearly a 98% success rate in application submissions, we are always by the side of businesses to present the most suitable subsidized programs that match their development needs and maximize their benefits.
